Hemostatic System and its Regulation in Disorders of Renal Function
DOI:
https://doi.org/10.22141/2307-1257.3.17.2016.76541Keywords:
hemostasis, impaired renal function, platelets, coagulation cascade, anticoagulants, antiplatelet agents, uremic bleeding and antithrombotic therapy, antithrombotic therapy in uremic patients, hemostasis system research algorithmAbstract
In various violations of kidney function, there is a change in the hemostatic system, which can manifest itself in the form of thrombosis or bleedings. In these processes, vascular endothelium, platelets, plasma proteins of clotting and anti-clotting systems are involved. For correction of hemostatic disorders in uremic patients, the antithrombotic therapy (anticoagulants, antiplatelets agents) is used in hypercoagulation, and desmopressin, cryoprecipitate, conjugated estrogens, recombinant human erythropoietin, transfusions of red blood cells — in bleedings. The algorithm for the study of hemostatic system is recommended, in its use it is possible to prescribe adequate therapy depending on the thromboembolic or hemorrhagic complications.
Downloads
References
.Jalal D.I., Chonchol M., Targher G. Disorders of hemostasis associated with chronic kidney disease // Semin. Thromb. Hemost. 2010; 36(1): 34-40.
Dolhov V.V.,Svirin P.V. Laboratory diagnosis of hemostatic disorders.— M.: RMAPE, 2005. — 227 p.
Spronk H., Govers-Riemslag J.W.P., ten Cate H. The blood coagulation system as a molecular machine // BioEssays. 2003; 25: 1220-1228.
Pavord S., Myers B. Bleeding and thrombotic complications of kidney disease // Blood Rev. 2011; 25: 271-278.
Parikh A.M., Spencer F.A., Lessard D. et al. Venous thromboembolism in patients with reduced estimated GFR: a populationbased perspective // Am. J. Kidney Dis. 2011; 58: 746-755.
Casserly L.F., Dember L.M. Thrombosis in end-stage renal disease // Semin. Dial. 2003; 16: 245-256.
Monreal M., Falga C., Valle R. et al. Venous thromboembolism in pa-tients with renal insufficiency: findings from the RIETE Registry // Am. J. Med. 2006; 119: 1073-1079.
Falga C., Capdevila J.A., Soler S. et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry // Thromb. Haemost. 2007; 98: 771-776.
Wattanakit K., Cushman M., Stehman-Breen C. et al. Chronic kidney disease increases risk for venous thromboembolism // J. Am. Soc. Nephrol. 2008; 19: 135-140.
Folsom A.R., Lutsey P.L., Astor B.C. et al. Chronic kidney disease and venous thromboembolism: a prospective study // Nephrol. Dial. Transplant. 2010; 25: 3296-3301.
Wattanakit K., Cushman M. Chronic kidney disease and venous throm-boembolism: epidemiology and mechanisms // Curr. Opin Pulm. Med. 2009; 15: 408-412.
Ocak G., Verduijn M., Vossen C.Y. et al. Chronic kidney disease stages 1–3 increase the risk of venous thrombosis // J. Thromb. Haemost. 2010; 8: 2428-2435.
Shlipak M.G., Fried L.F., Crump C. et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency // Circulation. 2003; 107: 87-92.
De la Serna G. Fibrinogen: a new major risk factor for cardiovascular disease. A review of the literature // J. Fam. Pract. 1994; 39: 468-477.
Pawlak K., Tankiewicz J., Mysliwiec M. et al. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on con-servative treatment // Blood Coagul. Fibrinolysis. 2009; 20: 590-594.
Cetin O., Bekpinar S., Unlucerci Y. et al. Hyperhomocysteinemia in chronic renal failure patients: relation to tissue factor and platelet aggrega-tion // Clin. Nephrol. 2006; 65: 97-102.
Takagi M., Wada H., Mukai K. et al. Increased activated protein C: pro-tein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis // Clin. Appl. Thromb. Hemost. 1999; 5: 113-116.
Tomura S., Nakamura Y., Deguchi F. et al. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment // Thromb. Res. 1991; 64: 81-90.
Tay K.H., Lip G.Y. What «drives» the link between the renin-angiotensin- aldosterone system and the prothrombotic state in hyperten-sion? // Am. J. Hypertens. 2008; 21: 1278-1279.
Sloand E.M., Bern M.M., Kaldany A. Effect on platelet function of hy-poalbuminemia in peritoneal dialysis // Thromb. Res. 1986; 44: 419-425.
Brunini T.M., Mendes-Ribeiro A.C., Ellory J.C. et al. Platelet nitricoxide synthesis in uremia and malnutrition: a role for L-arginine supplementation in vascular protection? // Cardiovasc. Res. 2007; 73: 359-367.
Jankowski J., van der Giet M., Jankowski V. et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS ex-pression // J. Clin. Invest. 2003; 112: 256-264.
Bonomini M., Dottori S., Amoroso L. et al. Increased platelet phospha-tidylserine exposure and caspase activation in chronic uremia // J. Thromb. Haemost. 2004; 2: 1275-1281.
Brunet P., Aillaud M.F., San Marco M. et al. Antiphospholipids in he-modialysis patients: relationship between lupus anticoagulant and throm-bosis // Kidney Int. 1995; 48: 794-800.
Chew S.L., Lins R.L., Daelemans R. et al. Are antiphospholipid anti-bodies clinically relevant in dialysis patients? // Nephrol. Dial. Transplant. 1992; 7: 1194-1198.
Prakash R., Miller C.C. III, Suki W.N. Anticardiolipin antibody in pa-tients on maintenance hemodialysis and its association with recurrent arte-riovenous graft thrombosis // Am. J. Kidney Dis. 1995; 26: 347-352.
Molino D., de Lucia D., Gaspare de Santo N. Coagulation disorders in uremia // Semin. Nephrol. 2006; 26: 46-51.
Camaioni C., Gustapane M., Cialdella P. et al. Microparticles and mi-croRNAs: new players in the complex field of coagulation // Intern. Emerg. Med. 2011.
Prandoni P., Bilora F., Marchiori A. et al. An association between ath-erosclerosis and venous thrombosis // N. Engl. J. Med. 2003; 348: 1435-1441.
Piazza G., Goldhaber S.Z., Lessard D.M. et al. Venous thromboembo-lism in patients with symptomatic atherosclerosis // Thromb. Haemost. 2011; 106: 1095-1102.
Mahmoodi B.K., Gansevoort R.T., Veeger N.J. et al. Microalbuminuria and risk of venous thromboembolism // JAMA. 2009; 301: 1790-1797.
Daniel L., Dou L., Berland Y. et al. Circulating microparticles in renal diseases // Nephrol. Dial. Transplant. 2008; 23: 2129-2132.
Freyssinet J.M., Toti F. Formation of procoagulant microparticles and properties // Thromb. Res. 2010; 125: S46-S48.
Connor D.E., Exner T., Ma D.D. et al. Detection of the procoagulant ac-tivity of microparticle-associated phosphatidylserine using XACT // Blood Coagul. Fibrinolysis. 2009; 20: 558-564.
Key N.S. Analysis of tissue factor positive microparticles // Thromb. Res. 2010; 125: S42-S45.
Landry P., Plante I., Ouellet D.L. et al. Existence of a microRNA path-way in anucleate platelets // Nat. Struct. Mol. Biol. 2009; 16: 961-966.
Moal V., Brunet P., Dou L. et al. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients // Nephrol. Dial. Transplant. 2003; 18: 1834-1841.
Glorieux G., Cohen G., Jankowski J. et al. Platelet/leukocyte activation, inflammation, and uremia // Semin. Dial. 2009; 22: 423-427.
Di Minno G., Martinez J., McKean M.L. et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis // Am. J. Med. 1985; 79: 552-559.
Eknoyan G., Brown C.H., 3rd. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphos-phate and Mg-dependent adenosine triphosphatase // Am. J. Nephrol. 1981; 1: 17-23.
Smith M.C., Dunn M.J. Impaired platelet thromboxane production in renal failure // Nephron. 1981; 29: 133-137.
Thekkedath U.R., Chirananthavat T., Leypoldt J.K. et al. Elevated fi-brinogen fragment levels in uremic plasma inhibit platelet function and ex-pression of glycoprotein IIb–IIIa // Am. J. Hematol. 2006; 81: 915-926.
Rabiner S.F., Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure // Am. J. Med. 1970; 49: 346-351.
Horowitz H.I. Uremic toxins and platelet function // Arch. Intern. Med. 1970; 126: 823-826.
Horowitz H.I., Stein I.M., Cohen B.D. et al. Further studies on the plate-let-inhibitory effect of guanidinosuccinic acid and its role in uremic bleeding // Am. J. Med. 1970; 49: 336-345.
Remuzzi G., Livio M., Marchiaro G. et al. Bleeding in renal failure: al-tered platelet function in chronic uraemia only partially corrected by hae-modialysis // Nephron. 1978; 22: 347-353.
Sirolli V., Ballone E., di Stante S. et al. Cell activation and cellular-cellular interactions during hemodialysis: effect of dialyzer membrane // Int. J. Artif. Organs. 2002; 25: 529-537.
Remuzzi G., Marchesi D., Livio M. et al. Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleed-ing times // Thromb. Res. 1978; 13: 1007-1015.
Boccardo P., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure // Semin. Thromb. Hemost. 2004; 30: 579-589.
Mezzano D., Tagle R., Panes O. et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlat-ed with indices of activation of coagulation and fibrinolysis // Thromb. Haemost. 1996; 76: 312-321.
Benigni A., Boccardo P., Galbusera M. et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia // Am. J. Kidney Dis. 1993; 22: 668-676.
Gawaz M.P., Dobos G., Spath M. et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease // J. Am. Soc. Nephrol. 1994; 5: 36-46.
Sreedhara R., Itagaki I., Hakim R.M. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of gly-coprotein IIb–IIIa receptors // Am. J. Kidney Dis. 1996; 27: 355-364.
Janson P.A., Jubelirer S.J., Weinstein M.J. et al. Treatment of the bleed-ing tendency in uremia with cryoprecipitate // N. Engl. J. Med. 1980; 303: 1318-1322.
Mannucci P.M., Remuzzi G., Pusineri F. et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia // N. Engl. J. Med. 1983; 308: 8-12.
Kyrle P.A., Stockenhuber F., Brenner B. et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure // Thromb. Haemost. 1988; 60: 205-208.
Defreyn G., Dauden M.V., Machin S.J. et al. A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells // Thromb. Res. 1980; 19: 695-699.
Galbusera M., Remuzzi G., Boccardo P. Treatment of bleeding in dialy-sis patients // Semin. Dial. 2009; 22: 279-286.
Fernandez F., Goudable C., Sie P. et al. Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions // Br. J. Haematol. 1985; 59: 139-148.
Howard A.D., Moore J. Jr, Welch P.G. et al. Analysis of the quantitative relationship between anemia and chronic renal failure // Am. J. Med. Sci. 1989; 297: 309-313.
Livio M., Gotti E., Marchesi D. et al. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions // Lancet. 1982; 2: 1013-1015.
Moia M., Mannucci P.M., Vizzotto L. et al. Improvement in the haemo-static defect of uraemia after treatment with recombinant human erythropoi-etin // Lancet. 1987; 2: 1227-1229.
Vigano G., Benigni A., Mendogni D. et al. Recombinant human eryth-ropoietin to correct uremic bleeding // Am. J. Kidney Dis. 1991; 18: 44-49.
D’Elia J.A., Weinrauch L.A., Gleason R.E. et al. Risk factors for throm-boembolic events in renal failure // Int. J. Cardiol. 2005; 101(1): 19-25.
Caglar K., Peng Y., Pupim L.B. et al. Inflammatory signals associated with hemodialysis // Kidney Int. 2002; 62(4): 1408-1416.
Ando M., Iwata A., Ozeki Y. et al. Circulated platelet-derived micropar-ticles with procoagulant activity may be a potential cause of thrombosis in uremic patients // Kidney Int. 2002; 62(5): 1757-1763.
Hirsh et al. and Kearon et al. Chest 2008 8th ACCP Conference on An-tithrombotic and Thrombolytic Therapy, 2008.
Lim W., Dentali F., Eikelboom J.W., Crowter M.A. Meta-analysis: lowmolecular-weight heparin and bleeding in patients with severe renal in-sufficiency // Ann. Intern. Med. 2006; 144(9): 673-684.
Schmid P., Fisher A.G., Wuillemin W.A. Low-molecular-weight heparin in patients with renal insufficiency // Swiss Med. WKLY. 2009; 139(31–32): 438-452.
Fareed J., Leong W.L., Hoppensteadt D.A. et al. Generic low-molecularweight heparins: some practical considerations // Semin. Thromb. Hemost. 2004; 30(6): 703-713.
Samama M.M., Gerotziafas G.T. Comparative pharmacokinetics of LMWHs // Semin. Thromb. Hemost. 2000; 26(Suppl. 1): 31-38.
Amiral J., Bridey F., Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocy-topenia (Letter) // Thromb. Haemost. 1992; 68: 95-6.
Kelton J.G., Sheridan D., Santos A. et al. Hepar-ininduced thrombocy-topenia: laboratory studies // Blood. 1988; 72: 925-30.
Newman P.M., Chong B.H. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation // Blood. 2000; 96: 182-7.
Warkentin T.E., Levine M.N., Hirsh J. et al. Heparin-induced thrombo-cytopenia in patients treated with low-molecular-weight heparin or unfrac-tionated heparin // N. Engl. J. Med. 1995; 332: 1330-5.
Warkentin T.E., Elavathil L.J., Hayward C.P.M., Johnston M.A., Rus-sett J.I., Kelton J.G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia // Ann. Intern. Med. 1997; 127: 804-12.
Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia / Warkentin T.E., Greinacher A. еds. // Heparin-Induced Thrombocytopenia, 2nd ed. — New York: Marcel Dekker Inc., 2001. — Р. 43-86.
Warkentin T.Е., Hayward C.P.M., Boshkov U.K. et al. Sera from pa-tients with heparin-induced thrombocytopenia generate platelet-derived mi-croparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia // Blood. 1994; 84: 3691-9.
Visentin G.P., Ford S.E., Scott J.P., Aster R.H. Antibodies from pa-tients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 com¬plexed with heparin or bound to endothelial cells // J. Clin. Invest. 1994; 93: 81-8.
Arepally G.M., Maver I.M. Antibodies from patients with heparin-induced thrombocvtopenia simulate monocytic cells to express tissue factor and secrete interleukin 8 // Blood. 2001; 98: 1252-4.
Warkentin T.E., Kelton J.G. A 14-year study of heparin-¬induced throm-bocy topenia // Am. J. Med. 1996; 101: 502-7.
Wallis D.E., Workman D.L., Lewis B.E., Steen L., Pifarre R., Moray J.F. Failure of early heparin cessation as treat ment fogy heparin-induced thrombocytopenia // Am. J. Med. 1999; 106: 629-35.
Grand’Maison A., Charest A.F., Geerts W.H. Anticoagulant use in pa-tients with chronic renal impairment // Am. J. Cardiovasc. Drugs. 2005; 5: 291-305.
Warfarin summary of product characteristics. Electronic Medicines Compendium. — http://www.medicines.org.uk/EMC/medicine/23642. Ac-cessed February 10, 2012.
Pradaxa approval package. Food and Drug Administration. — http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000Approv. pdf. Accessed February 10, 2012.
Pradaxa summary of product characteristics. European Medicine Agen-cy. — http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed Febru-ary 10, 2012.
Kubitza D., Becka M., Mueck W., Halabi A., Maatouk H., Klause N., Lufft V., Wand D.D., Philipp T., Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor // Br. J. Clin. Pharmacol. 2010; 70: 703-712.
Vane J.R., Botting R.M. The mechanism of action of aspirin // Thromb. Res. 2003; 110(5–6): 255-258.
Bonvalet J.P., Pradelles P., Farman N. Segmental synthesis and actions of prostaglandins along the nephron // Am. J. Physiol. 1987; 253: F377-F387.
Aspirin caplets summary of product characteristics. Electronic Medi-cines Compendium. — http://www.medicines.org.uk/emc/medicine/7951/SPC. Accessed February 10, 2012.
Plavix summary of product characteristics. Electronic Medicines Com-pendium. — http://www.medicines.org.uk/emc/medicine/9483/SPC. Ac-cessed February 10, 2012.
Plantinga L., Grubbs V., Sarkar U., Hsu C.Y., Hedgeman E., Robinson B., Saran R., Geiss L., Burrows N.R., Eberhardt M., Powe N.; CDC CKD Surveillance Team. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States // Ann. Fam. Med. 2011; 9: 423-430.
Small D.S., Wrishko R.E., Ernest C.S. 2nd, Ni L., Winters K.J., Farid N.A., Li Y.G., Brandt J.T., Salazar D.E., Borel A.G., Kles K.A., Payne C.D. Prasugrel pharmacokinetics and pharmacodynamics in subjects with mod-erate renal impairment and end-stage renal disease // J. Clin. Pharm. Ther. 2009; 34: 585-594.
Reopro summary of product characteristics. Electronic Medicines Com-pendium. — http://www.medicines.org.uk/EMC/medicine/610/SPC. Ac-cessed February 10, 2012.
Integrilin summary of product characteristics. Electronic Medicines Compendium. — http://www.medicines.org.uk/emc/medicine/15823/SPC. Accessed February 10, 2012.
Aggrastat summary of product characteristics. Electronic Medicines Compendium. http://www.medicines.org.uk/EMC/medicine/24563/SPC. Ac-cessed February 10, 2012.
Triulzi D.J., Blumberg N. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia // Yale J. Biol. Med. 1990; 63: 1-7.
Aledort L.M. New approaches to management of bleeding disorders // Hosp. Pract. (Off Ed.). 1989; 24: 207-11, 214, 219-21.
Eberst M.E., Berkowitz L.R. Hemostasis in renal dis-ease:pathophysiology and management // Am. J. Med. 1994; 96: 168-79.
Gralnick H.R., McKeown L.P., Williams S.B. et al. Plasma and platelet von Willebrand factor defects in uremia // Am. J. Med. 1988; 85: 806-10.
Ozen S., Saatci U., Bakkaloglu A. et al. Low-dose intranasal intranasal desmopressin (DDAVP) for uremic bleeding // Nephron. 1997; 75: 119-20.
Vigano G., Zoja C., Corna D. et al. 17β-Estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism // J. Pharmacol. Exp. Ther. 1990; 252: 344-8.
Norris M., Todeschini M., Zappella S. et al. 17β-Estradiol corrects he-mostasis in uremic rats by limiting vascular expression of nitric oxide syn-thases // Am. J. Physiol. Renal. Physiol. 2000; 279: F626-35.
Sloand J.A. Long-term therapy for uremic bleeding // Int. J. Artif. Or-gans. 1996; 19: 439-40.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 O.O. Melnyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 2307-1257
ISSN 2307-1265
